Celularity (CELU) Capital Expenditures (2020 - 2024)
Celularity (CELU) posted quarterly Capital Expenditures of $1.4 million for Q4 2024, up 148.97% year-over-year from $580000.0 in Q1 2024, and up 10414.29% quarter-over-quarter from -$14000.0 in Q3 2024.
Celularity (CELU) Capital Expenditures (2020 - 2024) Analysis & Trends
Celularity (CELU) has reported Capital Expenditures for 5 consecutive years, with $1.4 million the latest figure, recorded in Q4 2024.
- In Q4 2024, Capital Expenditures rose 148.97% year-over-year to $1.4 million; the TTM figure through Dec 2024 stood at $1.5 million (up 43.13% YoY), while the FY2024 annual figure was $1.5 million, up 43.13% from the prior year.
- Capital Expenditures improved to $1.4 million in Q4 2024 per CELU's latest filing, from -$14000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $9.4 million in Q4 2020 and bottomed at -$3.8 million in Q4 2022.
- Historically, Capital Expenditures has averaged $798411.8 across 5 years, with a median of $287000.0 in 2021.
- Annual changes were most pronounced in 2022 — Capital Expenditures soared 5468.57% — and 2023, when it tumbled 134.68%.
- Celularity's Capital Expenditures stood at $9.4 million in 2020, then tumbled by 131.26% to -$2.9 million in 2021, then retreated by 28.81% to -$3.8 million in 2022, then jumped by 115.37% to $580000.0 in 2023, then surged by 148.97% to $1.4 million in 2024.
- Business Quant data shows CELU's Capital Expenditures at $1.4 million in Q4 2024, -$14000.0 in Q3 2024, and $31000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 34.68 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.26 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 251.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -73.57 Mn |
| 10 | Celularity | 20.90 Mn | 14.72 Mn | -3.27 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 1.44 Mn |
| Dec 31, 2024 | 1.44 Mn |
| Sep 30, 2024 | -14,000.00 |
| Sep 30, 2024 | -14,000.00 |
| Jun 30, 2024 | 31,000.00 |
| Jun 30, 2024 | 31,000.00 |
| Mar 31, 2024 | 39,000.00 |
| Mar 31, 2024 | 39,000.00 |
| Dec 31, 2023 | 580,000.00 |
| Dec 31, 2023 | 580,000.00 |
| Sep 30, 2023 | -542,000.00 |
| Sep 30, 2023 | -542,000.00 |
| Jun 30, 2023 | 801,000.00 |
| Jun 30, 2023 | 801,000.00 |
| Mar 31, 2023 | 209,000.00 |
| Mar 31, 2023 | 209,000.00 |
| Dec 31, 2022 | -3.77 Mn |
| Dec 31, 2022 | -3.77 Mn |
| Sep 30, 2022 | 1.56 Mn |
| Sep 30, 2022 | 1.56 Mn |